Literature DB >> 11516830

Regulation of apolipoprotein E secretion in rat primary hippocampal astrocyte cultures.

A Cedazo-Mínguez1, U Hamker, V Meske, R W Veh, R Hellweg, C Jacobi, F Albert, R F Cowburn, T G Ohm.   

Abstract

Apolipoprotein E isoforms may have differential effects on a number of pathological processes underlying Alzheimer's disease. Recent studies suggest that the amount, rather than the type, of apolipoprotein E may also be an important determinant for Alzheimer's disease. Therefore, understanding the regulated synthesis of apolipoprotein E is important for determining its role in Alzheimer's disease. We show here that in rat primary hippocampal astrocyte cultures, dibutyryl-cAMP increased apolipoprotein E secretion with time in a dose-dependent manner (to 177% at 48 h) and that retinoic acid potentiated this effect (to 298% at 48 h). Dibutyryl-cAMP also gave a rapid, albeit transient, increase of apolipoprotein E mRNA expression (to 200% at 1 h). In contrast, the protein kinase C activator phorbol 12-myristate 13-acetate decreased both apolipoprotein E secretion (to 59% at 48 h) and mRNA expression (to 22% at 1 h). Phorbol 12-myristate 13-acetate also reversed the effects of dibutyryl-cAMP. Apolipoprotein E secretion was also modulated by receptor agonists for the adenylyl cyclase/cAMP pathway. Isoproterenol (50 nM, a beta-adrenoceptor agonist) enhanced, while clonidine (250 nM, an alpha2-adrenoceptor agonist) decreased, secreted apolipoprotein E. We also analysed the effects of agonists for the phospholipase C/protein kinase C pathway. Arterenol (1 microM, an alpha1-adrenoceptor agonist) and serotonin (2.5 microM) enhanced, whereas carbachol (10 microM, an acetylcholine muscarinic receptor agonist) decreased secreted apolipoprotein E. The effects of these non-selective receptor agonists were modest, probably due to effects on different signalling pathways. Arterenol also potentiated the isoproterenol-mediated increase. We also show that phorbol 12-myristate 13-acetate and dibutyryl-cAMP have opposite effects on nerve growth factor, as compared to apolipoprotein E, secretion, suggesting that the results obtained were unlikely to be due to a general effect on protein synthesis. We conclude that astrocyte apolipoprotein E production can be regulated by factors that affect cAMP intracellular concentration or activate protein kinase C. Alterations in these signalling pathways in Alzheimer's disease brain may have consequences for apolipoprotein E secretion in this disorder.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11516830     DOI: 10.1016/s0306-4522(01)00224-x

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  8 in total

1.  Side chain-oxidized oxysterols regulate the brain renin-angiotensin system through a liver X receptor-dependent mechanism.

Authors:  Laura Mateos; Muhammad-Al-Mustafa Ismail; Francisco-Javier Gil-Bea; Rebecca Schüle; Ludger Schöls; Maura Heverin; Ronnie Folkesson; Ingemar Björkhem; Angel Cedazo-Mínguez
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

Review 2.  Evidence for defective retinoid transport and function in late onset Alzheimer's disease.

Authors:  Ann B Goodman; Arthur B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

3.  AP-2β regulates amyloid beta-protein stimulation of apolipoprotein E transcription in astrocytes.

Authors:  Ximena S Rossello; Urule Igbavboa; Gary A Weisman; Grace Y Sun; W Gibson Wood
Journal:  Brain Res       Date:  2012-01-18       Impact factor: 3.252

Review 4.  Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis.

Authors:  W Gibson Wood; Ling Li; Walter E Müller; Gunter P Eckert
Journal:  J Neurochem       Date:  2014-01-02       Impact factor: 5.372

Review 5.  Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease.

Authors:  Yadong Huang; Karl H Weisgraber; Lennart Mucke; Robert W Mahley
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 6.  Plasticity and the spread of Alzheimer's disease-like changes.

Authors:  Thomas G Ohm; Frauke Glöckner; Roland Distl; Stefanie Treiber-Held; Volker Meske; Bärbel Schönheit
Journal:  Neurochem Res       Date:  2003-11       Impact factor: 3.996

7.  Hypercholesterolemia and 27-Hydroxycholesterol Increase S100A8 and RAGE Expression in the Brain: a Link Between Cholesterol, Alarmins, and Neurodegeneration.

Authors:  Raúl Loera-Valencia; Muhammad-Al-Mustafa Ismail; Julen Goikolea; Maria Lodeiro; Laura Mateos; Ingemar Björkhem; Elena Puerta; Mariana A Romão; Cláudio M Gomes; Paula Merino-Serrais; Silvia Maioli; Angel Cedazo-Minguez
Journal:  Mol Neurobiol       Date:  2021-08-27       Impact factor: 5.590

Review 8.  Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities.

Authors:  Angel Cedazo-Mínguez
Journal:  J Cell Mol Med       Date:  2007 Nov-Dec       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.